Phathom Pharmaceuticals/$PHAT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Phathom Pharmaceuticals
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Ticker
$PHAT
Sector
Primary listing
Employees
427
Headquarters
Website
PHAT Metrics
BasicAdvanced
$823M
-
-$4.71
0.45
-
Price and volume
Market cap
$823M
Beta
0.45
52-week high
$17.94
52-week low
$2.21
Average daily volume
1.2M
Financial strength
Current ratio
2.384
Quick ratio
2.187
Long term debt to equity
-136.196
Total debt to equity
-141.559
Interest coverage (TTM)
-3.70%
Profitability
EBITDA (TTM)
-268.266
Gross margin (TTM)
86.91%
Net profit margin (TTM)
-289.51%
Operating margin (TTM)
-235.88%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-59.03%
Return on equity (TTM)
103.23%
Valuation
Price to revenue (TTM)
7.261
Price to book
-2.04
Price to tangible book (TTM)
-2.04
Price to free cash flow (TTM)
-3.013
Free cash flow yield (TTM)
-33.19%
Free cash flow per share (TTM)
-3.923
Growth
Revenue change (TTM)
1,049.82%
Earnings per share change (TTM)
-8.32%
3-year earnings per share growth (CAGR)
2.82%
What the Analysts think about PHAT
Analyst ratings (Buy, Hold, Sell) for Phathom Pharmaceuticals stock.
Bulls say / Bears say
The FDA’s recognition of a full 10-year New Chemical Entity exclusivity for VOQUEZNA® extends protection through May 3, 2032, safeguarding Phathom’s primary revenue driver from generic competition for seven more years (Nasdaq)
VOQUEZNA® has been added to CVS Caremark formularies for commercially insured patients, enhancing payer coverage and facilitating patient access to Phathom’s flagship product (FT)
The stock’s Relative Strength rating was upgraded from 79 to 84, indicating improved price performance and approaching benchmarks typical of emerging market leaders (Investor’s Business Daily)
Phathom reported 0% earnings growth in its latest quarter despite robust 440% sales growth, underscoring persistent profitability challenges and high operating expenses (Investor’s Business Daily)
FDA exclusivity alone does not ensure commercial success; Phathom faces reimbursement and payer acceptance risks for VOQUEZNA®, particularly against entrenched, lower-cost PPIs (Nasdaq)
After its RS upgrade, PHAT stock fell below its 12.32 entry point, signaling a failed technical breakout and heightened investor caution (Investor’s Business Daily)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
PHAT Financial Performance
Revenues and expenses
PHAT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Phathom Pharmaceuticals stock?
Phathom Pharmaceuticals (PHAT) has a market cap of $823M as of October 12, 2025.
What is the P/E ratio for Phathom Pharmaceuticals stock?
The price to earnings (P/E) ratio for Phathom Pharmaceuticals (PHAT) stock is 0 as of October 12, 2025.
Does Phathom Pharmaceuticals stock pay dividends?
No, Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Phathom Pharmaceuticals dividend payment date?
Phathom Pharmaceuticals (PHAT) stock does not pay dividends to its shareholders.
What is the beta indicator for Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.